Search

Displaying results 4451 - 4460 of 10000 in total
  1. Drug

    Limonene, (+/-)-

    go.drugbank.com/drugs/DB19146
    Investigational

    Limonene, (+/-)- is under investigation in clinical trial NCT05525260 (Limonene for Pulmonary Nodule Chemoprevention).

  2. Drug

    Phenazepam

    go.drugbank.com/drugs/DB19164
    Investigational

    Phenazepam is under investigation in clinical trial NCT03017430 (Pregabalin for Opiate Withdrawal Syndrome).

  3. Drug

    Brentuximab

    go.drugbank.com/drugs/DB05471
    Investigational

    SGN-30 has demonstrated objective antitumor responses as a single agent in phase II clinical trials. … SGN-30 received orphan drug designation from the FDA in July 2003 for Hodgkin lymphoma and in February 2004 for T-cell lymphomas.

  4. Drug

    Solanezumab

    go.drugbank.com/drugs/DB11756
    Investigational

    Solanezumab is under investigation for the treatment of Dementia, Alzheimers Disease, and Alzheimers Disease, Familial.

  5. Drug

    Pimonidazole

    go.drugbank.com/drugs/DB12485
    Investigational

    Pimonidazole is under investigation for the diagnostic of Prostate Cancer and Head and Neck Cancer.

  6. Drug

    FLX475

    go.drugbank.com/drugs/DB15570
    Investigational

    FLX475 is a small molecule CCR4 antagonist being investigated for the treatment of cancer.[L9875]

  7. Drug

    Glucagon-like peptide II

    go.drugbank.com/drugs/DB12788
    Investigational

    Glucagon-like peptide II is under investigation for the basic science of Short Bowel Syndrome.

  8. Drug

    Urocortin-2

    go.drugbank.com/drugs/DB13033
    Investigational

    Urocortin 2 has been investigated for the basic science of Heart Failure and Cardiovascular Disease.

  9. Drug

    NXC680

    go.drugbank.com/drugs/DB18366
    Experimental

    NXC680 is a small molecule under investigation for the treatment of idiopathic pulmonary fibrosis (IPF).

  10. Drug

    Daglutril

    go.drugbank.com/drugs/DB05796
    Investigational

    Daglutril is an orally active, mixed neutral endopeptidase/endothelin converting enzyme inhibitor under development for the treatment of essential hypertension and congestive heart failure.